Safety, Tolerability, and Pharmacokinetics of GDC-0276, a Novel NaV1.7 Inhibitor, in a First-in-Human, Single- and Multiple-Dose Study in Healthy Volunteers

• Published in: Clinical drug investigation Vol. 39; no. 9; pp. 873 - 887
• Main Authors: Rothenberg, Michael E., Tagen, Michael, Chang, Jae H., Boyce-Rustay, Janel, Friesenhahn, Michel, Hackos, David H., Hains, Avis, Sutherlin, Dan, Ward, Michael, Cho, William
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01.09.2019; Springer Nature B.V
• Subjects: Drug dosages; Inhibitor drugs; Internal Medicine; Medicine; Medicine & Public Health; Mutation; Narcotics; Nonsteroidal anti-inflammatory drugs; Original Research Article; Pain; Pharmacokinetics; Pharmacology/Toxicology; Pharmacotherapy; Vital signs; United States > US

Background and Objective Current pain therapies often do not provide adequate pain relief and have dose-limiting adverse effects. Genetic evidence indicates that Na V 1.7 sodium channels are required for pain transduction and therefore represent an important therapeutic target. GDC-0276 is a novel N...